Hemostatic therapy for treatment of oral anticoagulation-related ICH


Hemostatic therapy for treatment of oral anticoagulation-related ICH

Hemostatic therapy for

treatment of oral

anticoagulation-related ICH

Michael N. Diringer, MD, FCCM, FAHA

Professor of Neurology, Neurosurgery & Anesthesiology

Director, Neurology/Neurosurgery Intensive Care Unit

Washington University School of Medicine

St. Louis, MO USA

FINANCIAL DISCLOSURE: No relevant financial relationship exists

OFF LABEL USE: Everything discussed


• 65 year old woman with a prosthetic

aortic valve taking warfarin

• Presents within 2 hours of onset of a

spontaneous lobar intracerebral


• INR is 2.3 and ICH volume is 25 cc

The Controversy

Should PCC or rFVIIa be used for

acute treatment of

anticoagulation-related ICH ?

OAC related intracerebral


Larger size predicts worse


Zubkov AY, Arch Neurol 2008;65:1320

Expansion more common with longer

time window

• Hematoma expansion in 28% OAC-ICH

patients admitted within 24 hours despite


Yasaka M, Thromb Haemost. 2003;89:278 –283

• Hematoma expansion up to day 7



No anticoagulants 16%

On anticoagulants 54%

Flibotte JJ, Neurology, 2004;63:1059

Goal: Rapid correction of

warfarin induced coagulopathy


• Vitamin K

• Recombinant activated Factor VII (rFVIIa)

• Fresh Frozen Plasma (FFP)

• Prothrombin Complex Concentrate (PCC)

Vitamin K

• Takes hours to days to achieve an

effective response

• Still necessary when using rFVIIa, FFP

or PCC

• More rapid when given intravenously

– Adverse events: 3 per 10,000

Fresh Frozen Plasma (FFP)

• Contains all coagulation factors

• Takes time:

• Requires compatibility testing and


• Large volume to infuse

• Median 30 hours until INR


Brody DL, Neurocrit Care. 2005;2(3):263-7

Transfusion related acute lung injury


• Hypoxia and bilateral

pulmonary edema

• Independent predictor of


• FFP higher risk than other

blood products

Toy P, Blood. 2011 Nov 23. [Epub],

Triulzi DJ, Anesth Analg 2009 108; 770

Other risks of FFP

• Circulatory overload

• Blood-borne infection


• Allergic reactions

Recombinant activated Factor VII

• 5µg/kg (1 mg for 100 kg patient) corrects

therapeutic INR in minutes


• Replaces only 1 factor – may not correct


• rFVIIa interferes with INR assay

– INR no longer reflects bleeding tendency

– No way to monitor need for additional


FVIIa normalizes INR but not bleeding

from punch biopsy

Group n Baseline



After drug

Placebo 24 1.0 ± 0.1 2.5 ± 0.3 2.5 ± 0.3

5 μg/kg rFVIIa 6 1.1 ± 0.1 2.7 ± 0.3 1.5 ± 0.5

10 μg/kg rFVIIa 6 1.1 ± 0.1 2.6 ± 0.2 1.3 ± 0.1

Skolnick B E et al. Blood 2010;116:693-701

FVIIa normalizes INR but not bleeding

from punch biopsy


Baseline Coumadin rFVIIa

Skolnick B E et al. Blood 2010;116:693-701

Prothrombin complex

concentrates (PCC)

• Contain prothrombin and factors IX, X,

and usually VII

• Some contain protein C and S

• Immediately available

• Reconstituted in small volume of fluid

• ? Potential to induce thrombosis

Literature review: PCC for warfarin


• 14 studies (460 patients) who received

PCC for warfarin reversal

• PCCs correct INR faster than FFP

• Seven (1.5%) thrombotic complications

• 3 strokes (occurred >48 hours after


• 2 DVTs

• 2 non-Q wave MIs

Leissinger C, Am J Hematol 83:137–143, 2008

Literature review: PCC thrombogenicity

• Conclusions

– With the inclusion of coagulation

inhibitors and other manufacturing

improvements, today's PCCs may be

considered safer than earlier products

– PCCs may be considered preferable

to fresh frozen plasma for emergency

anticoagulant reversal

Sørensen B, Crit Care. 2011; 15(1): 201

FFP vs. PCC in OAC-related ICH

• Retrospective

• 55 patients with ICH while on OAC

• Hematoma growth in 27% within 24 hours

• Hematoma growth less with PCC

• Difference no longer seen if INR

completely reversed within 2 hours

Huttner HB, Stroke. 2006 Jun;37(6):1465-70

PCC in OAC-related ICH

• Prospective

• 92 acute ICH patients on warfarin with INR ≥ 2.0

• Treated with PCC (Protromplex, no FVII) and

vitamin K

• No thrombotic


Imberti A et al. Pathophysiol Haemost Thromb 2007–08;36:259–265

Survey of practice

• Treat a hypothetical case of OACrelated


• Option to give vitamin K, FFP,

rFVIIa, PCC or combination


North America 10% 70%

Europe, Asia, South


81% 22%

Neal M et al. Thromb Res 2008; 122:864–866




Results from

• Efficacy and Safety Study of BERIPLEX ®

Compared With Plasma in Patients With

Acute Major Bleeding Caused by

Anticoagulant Therapy


• Give vitamin K

• Give PCC

More magazines by this user
Similar magazines